GoodRx Holdings (GDRX)
NASDAQ:GDRX
Want to see GDRX full AI Analyst Report?
GDRX Stock Chart & Stats
$2.27
-$0.12(-2.72%)
At close: 4:00 PM EST
$2.27
-$0.12(-2.72%)
Day’s Range― - ―
52-Week Range$1.77 - $5.81
Previous CloseN/A
Volume261.88K
Average Volume (3M)1.67M
Market Cap
$787.92M
Enterprise Value$589.35M
Total Cash (Recent Filing)$261.82M
Total Debt (Recent Filing)$59.54M
Price to Earnings (P/E)42.5
Beta0.77
Next Earnings
May 07, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding108,610,310
10 Day Avg. Volume1,403,391
30 Day Avg. Volume1,671,235
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)1.21
P/FCF Ratio5.87
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue0.74
Enterprise Value/Gross Profit0.90
Enterprise Value/Ebitda3.20
Forecast
1Y Price Target
$2.84Price Target Upside25.11% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)0.32
Revenue Forecast (FY)$764.76M
Bulls Say, Bears Say
Bulls Say
Capital Allocation And Cash FlowStrong free cash flow supports opportunistic share repurchases under the existing authorization, which can bolster shareholder value while the business executes its strategy.
Pharma Direct ExpansionLower take rates combined with a large consumer audience enable scaling of Pharma Direct to capture strong demand for newer branded treatments, supporting revenue diversification beyond the core platform.
Subscription Unit EconomicsCondition-specific subscription offerings show early traction with customer acquisition costs below industry norms, signaling potential for meaningful recurring revenue as marketing ramps.
Bears Say
Core Prescription Transaction WeaknessDeclining prescription volumes, concessions on administrative fees, and evolving PBM models are eroding the larger prescription transaction business and limiting the offset from Pharma Direct growth.
Retail Partner DisruptionsStore closures and reduced volume at pharmacy partners are lowering prescription access and consumer engagement, which undermines prescription transaction revenue and proprietary pricing data.
Take Rate PressureAn unexpected reduction in take rates forces passing more economics to pharmacy partners, creating structural headwinds for prescription transaction revenue and compressing margins.
GoodRx Holdings News
GDRX FAQ
What was GoodRx Holdings’s price range in the past 12 months?
GoodRx Holdings lowest stock price was $1.77 and its highest was $5.81 in the past 12 months.
What is GoodRx Holdings’s market cap?
GoodRx Holdings’s market cap is $787.92M.
When is GoodRx Holdings’s upcoming earnings report date?
GoodRx Holdings’s upcoming earnings report date is May 07, 2026 which is in 12 days.
How were GoodRx Holdings’s earnings last quarter?
GoodRx Holdings released its earnings results on Feb 25, 2026. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.092 by -$0.002.
Is GoodRx Holdings overvalued?
According to Wall Street analysts GoodRx Holdings’s price is currently Undervalued.
Does GoodRx Holdings pay dividends?
GoodRx Holdings does not currently pay dividends.
What is GoodRx Holdings’s EPS estimate?
GoodRx Holdings’s EPS estimate is 0.07.
How many shares outstanding does GoodRx Holdings have?
GoodRx Holdings has 108,610,310 shares outstanding.
What happened to GoodRx Holdings’s price movement after its last earnings report?
GoodRx Holdings reported an EPS of $0.09 in its last earnings report, missing expectations of $0.092. Following the earnings report the stock price went down -18.776%.
Which hedge fund is a major shareholder of GoodRx Holdings?
Currently, no hedge funds are holding shares in GDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GoodRx Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.84 (25.11% Upside)
$2.84 (25.11% Upside)
Blogger Sentiment
Bullish
GDRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.38%
12-Months-Change
Fundamentals
Return on Equity
4.84%
Trailing 12-Months
Asset Growth
2.03%
Trailing 12-Months
Company Description
GoodRx Holdings
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
GDRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but strategically coherent picture: GoodRx demonstrated strong growth and momentum in its Pharma Direct business, meaningful platform scale (including a notable share of Wegovy pill self-pay fills), e-commerce expansion (tripled retail footprint, 83% QoQ order volume growth), and maintained positive adjusted EBITDA and cash reserves. However, the company is navigating material near-term headwinds in its legacy prescription transactions business—driven by lower unit economics, a 6% decline in prescription transactions revenue, a 14% drop in monthly active consumers, one-time partner impacts (~$35M–$40M), and guidance that implies revenue and EBITDA declines in 2026. Management framed 2026 as a transition year in which it will accept near-term pressure to invest in Pharma Direct, subscriptions, and longer-term durability. Given the balance of meaningful growth in strategic areas against tangible near-term financial and volume headwinds, the overall tone is balanced and transitional rather than clearly positive or negative.View all GDRX earnings summariesGDRX Revenue Breakdown
73.41% Prescription transactions
12.58% Subscription
11.34% Pharma manufacturer solutions
2.67% Other
GDRX Stock 12 Month Forecast
Average Price Target
$2.84
▲(25.11% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---